Does Dr. ANKUSH ASIJA have financial conflicts of interest?

Dr. ANKUSH ASIJA (MD) has received a total of $483 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $483 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ANKUSH ASIJA?

According to CMS Open Payments data, Dr. ANKUSH ASIJA received funding from ZOLL SERVICES (A/K/A ZOLL LIFECOR ) ($136), GLAXOSMITHKLINE ($122), and CALLIDITAS THERAPEUTICS US ($110).

Does Dr. ANKUSH ASIJA receive research grants or speaking fees?

Dr. ANKUSH ASIJA has received $483 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. ANKUSH ASIJA

MDReal-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: PUYALLUP, WA 98372

NPI Number: 1952742298

LIFETIME INDUSTRY VALUE

$483

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ASIJA is a verified Internal Medicine, Nephrology practitioner based in PUYALLUP, WA.

Between 2021 and 2024, Dr. ASIJA had an overall industry promotional and research financial footprint of $483 as recorded in the federal CMS Open Payments database.

$483 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ASIJA's primary funding source is ZOLL SERVICES (A/K/A ZOLL LIFECOR ), which accounts for $136 (representing 28.2% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ZOLL SERVICES (A/K/A ZOLL LIFECOR )

Rank 1

$136

28.2%

GLAXOSMITHKLINE

Rank 2

$122

25.2%

CALLIDITAS THERAPEUTICS US

Rank 3

$110

22.7%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.